Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.6 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare Solutions reported strong consolidated revenue of Rs. 17,065.18 million for Q3 FY26, up about 25.6% from Rs. 13,589.96 million in Q3 FY25. For the nine months ended December 2025, revenue rose to Rs. 46,812.85 million from Rs. 37,567.24 million, a growth of roughly 24.6%. Consolidated profit after tax for the nine months stood at Rs. 1,007.12 million versus Rs. 760.11 million last year, an increase of about 32.5%. Basic EPS for 9M FY26 improved to Rs. 20.00 from Rs. 15.90. The board recognised an exceptional item of Rs. 81.78 million (consolidated) due to a reassessment of employee benefit obligations under the New Labour Codes that came into effect from November 21, 2025. Statutory auditors MSKA & Associates issued an unmodified review opinion. The board also approved 5,000 fresh ESOPs at Rs. 804 per option and cancelled its earlier proposed acquisition of Khera Medisolutions and AV Medisolutions for commercial reasons.
Strong revenue and profit growth reflect healthy business expansion through ongoing acquisitions. The New Labour Codes exceptional charge is a one-time accounting adjustment and should not materially affect long-term earnings. Cancellation of two acquisitions removes some inorganic growth optionality but is unlikely to impact near-term performance.